Burosumab

Phase 1/2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

X-linked Hypophosphatemia (XLH)

Conditions

X-linked Hypophosphatemia (XLH)

Trial Timeline

Feb 26, 2020 → Mar 6, 2024

NCT ID

NCT04188964

About Burosumab

Burosumab is a phase 1/2 stage product being developed by Kyowa Kirin for X-linked Hypophosphatemia (XLH). The current trial status is completed. This product is registered under clinical trial identifier NCT04188964. Target conditions include X-linked Hypophosphatemia (XLH).

What happened to similar drugs?

2 of 8 similar drugs in X-linked Hypophosphatemia (XLH) were approved

Approved (2) Terminated (0) Active (6)

🔄KRN23Kyowa KirinPhase 3

🔄burosumab + Oral Phosphate Supplement + active vitamin DKyowa KirinPhase 3

🔄burosumabKyowa KirinPhase 3

✅KRN23Kyowa KirinApproved

🔄BurosumabKyowa KirinPhase 3

🔄burosumabKyowa KirinPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03775187	Pre-clinical	Active	—	—	X-linked Hypophosphatemia
NCT05181839	Pre-clinical	Completed	Nov 24, 2021	May 22, 2024	X-Linked Hypophosphatemia
NCT04695860	Phase 3	Completed	Jan 7, 2021	Mar 17, 2023	X-linked Hypophosphatemia
NCT04188964	Phase 1/2	Completed	Feb 26, 2020	Mar 6, 2024	X-linked Hypophosphatemia (XLH)
NCT03920072	Phase 3	Completed	Mar 7, 2019	Apr 7, 2022	X-linked Hypophosphatemia
NCT02750618	Phase 2	Completed	May 5, 2016	Sep 10, 2019	X-Linked Hypophosphatemia
NCT02537431	Phase 3	Completed	Dec 23, 2015	Dec 13, 2018	X-linked Hypophosphatemia
NCT02526160	Phase 3	Completed	Oct 22, 2015	Dec 6, 2018	X-linked Hypophosphatemia
NCT02304367	Phase 2	Completed	Mar 24, 2015	Jan 21, 2021	Tumor Induced Osteomalacia (TIO)
NCT02163577	Phase 2	Completed	Jul 2, 2014	Oct 30, 2018	X-linked Hypophosphatemia

Competing Products

20 competing products in X-linked Hypophosphatemia (XLH)

See all competitors

Product	Company	Stage	Hype Score
VK0214	Viking Therapeutics	Phase 1	26
Methylprednisolone + Prednisolone + Sirolimus	Astellas Pharma	Phase 1/2	39
Burosumab	Kyowa Kirin	Pre-clinical	30
Burosumab	Kyowa Kirin	Pre-clinical	26
Burosumab	Kyowa Kirin	Phase 2	35
KRN23	Kyowa Kirin	Phase 1/2	32
KRN23	Kyowa Kirin	Phase 3	40
burosumab + Oral Phosphate Supplement + active vitamin D	Kyowa Kirin	Phase 3	40
burosumab	Kyowa Kirin	Phase 3	40
KRN23	Kyowa Kirin	Approved	43
burosumab	Kyowa Kirin	Phase 2	35
Burosumab	Kyowa Kirin	Phase 3	40
KRN23	Kyowa Kirin	Phase 1/2	32
Placebo + KRN23	Kyowa Kirin	Phase 1	29
Burosumab	Kyowa Kirin	Phase 3	40
burosumab	Kyowa Kirin	Phase 3	40
KRN23	Kyowa Kirin	Phase 2	35
KRN23	Kyowa Kirin	Phase 1	29
KRN23	Kyowa Kirin	Approved	43
KK8123	Kyowa Kirin	Phase 1/2	39